Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States

Raquel Aguiar-Ibáñeza Merck Canada Inc., Kirkland, QC, CanadaCorrespondence[email protected]

Chloë Hardernb BresMed Health Solutions Ltd., Sheffield, UK

Frank van Heesc BresMed Health Solutions Ltd, Utrecht, Netherlands

Dawn Leeb BresMed Health Solutions Ltd., Sheffield, UK

Anubhav Pateld Complete HEOR Solutions (CHEORS), North Wales, PA, USA

Nitika Chhabrad Complete HEOR Solutions (CHEORS), North Wales, PA, USA

Gargi Balunid Complete HEOR Solutions (CHEORS), North Wales, PA, USA

Mayur Amonkare Merck & Co., Inc., Kenilworth, NJ, USA

Yizhen Laie Merck & Co., Inc., Kenilworth, NJ, USA

Ruifeng Xue Merck & Co., Inc., Kenilworth, NJ, USA

Rachid Massaadf MSD (Europe) Inc., Brussels, Belgium

David Fogelmane Merck & Co., Inc., Kenilworth, NJ, USA

Your download is now in progress and you may close this window